Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
Completed
1
100.0%
No approval data available
- SphingoTec will co-host a Scientific Symposium with partner Boditech at ESICM Lives 2026 (October 10–14, Lisbon), focusing on innovations in sepsis diagnostics. - New clinical data on penKid from a multicenter sepsis study will be presented as a poster at the ESICM congress. - At ASN Kidney Week 2026 (October 22–25, Denver), penKid will feature in a poster titled "Proenkephalin Predicts Severe AKI in High-Risk Patients." - The engagements reflect SphingoTec's strategy to expand the clinical and commercial reach of its penKid and bio-ADM biomarker portfolio in critical care.
- A comprehensive real-world study of over 4,000 ICU patients demonstrates that Proenkephalin A 119-159 (penKid) significantly outperforms traditional creatinine markers in detecting acute kidney injury and assessing kidney function. - PenKid successfully identifies high-risk patients at ICU admission, particularly those with normal serum creatinine levels, and predicts AKI development within 24-48 hours more accurately than conventional methods. - The biomarker maintains its diagnostic effectiveness during renal replacement therapy, providing dynamic insights into kidney recovery that could optimize treatment duration and reduce unnecessary interventions. - International recognition from Mayo Clinic researchers confirms penKid's clinical value, highlighting its ability to detect rapid kidney function changes and predict major adverse kidney events in critically ill patients.
